How to use and recommended dosage of pazopanib/pazopanib

Pazopanib is an oral multi-target tyrosine kinase inhibitor (TKI) mainly used to treat advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). As a targeted drug, it inhibits key signaling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-KIT), thereby preventing tumor angiogenesis and inhibiting the growth and spread of cancer cells. Correct dosing and recommended dosage are critical when treating pazopanib to ensure maximum efficacy while minimizing the incidence of side effects.

Based on the recommendations of clinical studies and drug inserts, the standard dose of pazopanib is 800 mg per day taken orally once, and the capsule should not be chewed, crushed or broken. This drug should be taken on an empty stomach, that is, at least 1 hour before or 2 hours after a meal to avoid food affecting the absorption of the drug. The medication should be taken with a full glass of water, and avoid taking it with grapefruit or grapefruit juice, as this may affect drug metabolism and lead to abnormally high blood drug concentrations, thereby increasing the risk of side effects.

For some specific patients, such as those with impaired liver function or poor tolerance, doctors may adjust the dose based on the specific situation. For patients with mild to moderate hepatic impairment, the recommended starting dose is 200 mg to 400 mg daily, while for patients with severe hepatic impairment, pazopanib is generally not recommended. In addition, if the patient experiences serious adverse reactions, such as high blood pressure, elevated liver enzymes, severe fatigue, or gastrointestinal reactions, the doctor may appropriately reduce the dose based on the patient's tolerance, such as adjusting to 600 mg or 400 mg once daily, while closely monitoring the patient's physical response.

Reference materials:https://www.votrient.com/